Results 1 to 10 of about 49 (44)

Structural insights into the binding behavior of isoflavonoid glabridin with human serum albumin

Food Hydrocolloids, 2019
Md Abdur Razzak, Shin Sik Choi
exaly  

Effect of Temperature on Binding of Warfarin by Human Serum Albumin

Journal of Pharmaceutical Sciences, 1976
exaly  

Binding of brucine to human serum albumin

Journal of Molecular Structure, 2007
exaly  

Effects of Phenylbutazone, Tolbutamide, and Clofibric Acid on Binding of Racemic Warfarin and Its Enantiomers to Human Serum Albumin

Journal of Pharmaceutical Sciences, 1979
exaly  

SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy [PDF]

Frontiers in Immunology, 2023
BackgroundThe potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short ...
John K. Cini, Susan Dexter, Darrel J. Rezac, Stephen J. McAndrew, Gael Hedou, Rich Brody, Rukiye-Nazan Eraslan, Richard T. Kenney, Pankaj Mohan   +8 more
doaj   +4 more sources

Bordetella pertussis and Bordetella bronchiseptica filamentous hemagglutinins are processed at different sites. [PDF]

FEBS Open Bio, 2018
Filamentous hemagglutinins (FHA) of Bordetellae are produced by processing of the ~ 130‐kDa C‐terminal prodomains of their FhaB precursors by the subtilisin‐like protease SphB1. Despite near‐complete sequence conservation of the processed FhaB segments, the SphB1 cleavage sites of FhaB from B. pertussis and B.
Jurnecka D, Man P, Sebo P, Bumba L.
europepmc   +2 more sources

SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy [PDF]

Frontiers in Immunology
BackgroundCytokines have been promising cancer immunotherapeutics for decades, yet only two are licensed to date. Interleukin-12 (IL-12) is a potent regulator of cell-mediated immunity that activates NK cells and interferon-γ (IFNγ) production.
John K. Cini, Richard T. Kenney, Susan Dexter, Stephen J. McAndrew, Rukiye-Nazan Eraslan, Rich Brody, Darrel J. Rezac, Rebecca Boohaker, Suzanne E. Lapi, Pankaj Mohan   +9 more
doaj   +2 more sources

A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers

Frontiers in Immunology
BackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 study
Richard T. Kenney, John K. Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P. Chawla, Thomas M. Polasek, Thomas M. Polasek, Jason Lickliter, Philip J. Ryan   +10 more
doaj   +3 more sources

The Recruitment and Activation of Plasminogen by Bacteria-The Involvement in Chronic Infection Development. [PDF]

Int J Mol Sci, 2023
Satala D, Bednarek A, Kozik A, Rapala-Kozik M, Karkowska-Kuleta J.   +4 more
europepmc   +1 more source

Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant <i>Candida auris</i>. [PDF]

J Fungi (Basel), 2023
Singh S, Barbarino A, Youssef EG, Coleman D, Gebremariam T, Ibrahim AS.   +5 more
europepmc   +1 more source